Adial Pharmaceuticals Announces Board and Compensation Changes
Ticker: ADIL · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1513525
| Field | Detail |
|---|---|
| Company | Adial Pharmaceuticals, Inc. (ADIL) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
Adial Pharma shakes up board, updates exec pay.
AI Summary
Adial Pharmaceuticals, Inc. announced on December 5, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of a director and the election of a new director, along with updates to its compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Adial Pharmaceuticals, Inc. (company) — Registrant
- December 5, 2024 (date) — Date of earliest event reported
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but does not name the individual in the provided text.
Who was elected to the board of directors?
The filing indicates the election of a new director, but does not name the individual in the provided text.
What specific compensatory arrangements were updated?
The filing mentions updates to compensatory arrangements of certain officers, but the specific details are not provided in the text.
What is the CIK number for Adial Pharmaceuticals, Inc.?
The CIK number for Adial Pharmaceuticals, Inc. is 0001513525.
What is the filing date of this 8-K report?
The filing date of this 8-K report is December 6, 2024.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-12-06 17:07:47
Filing Documents
- ea0223975-8k_adialpharm.htm (8-K) — 39KB
- ea022397501ex10-1_adialpharm.htm (EX-10.1) — 200KB
- 0001213900-24-106554.txt ( ) — 456KB
- adil-20241205.xsd (EX-101.SCH) — 3KB
- adil-20241205_lab.xml (EX-101.LAB) — 33KB
- adil-20241205_pre.xml (EX-101.PRE) — 22KB
- ea0223975-8k_adialpharm_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 6, 2024 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer 2